Mabxience Sets Out Investment Plans Under Fresenius Ownership

New Bioreactor At Genhelix Site In Spain Is A Milestone For Biosimilars Developer

 
• By Dave Wallace

Unveiling plans to install a new bioreactor at its Genhelix site in Spain, mAbxience is bolstering its biosimilars manufacturing capabilities and CDMO capacity under the majority ownership of Fresenius Kabi.

Capacity building
mAbxience is expanding capacity at its Genhelix site • Source: Shutterstock

More from Manufacturing

More from Business